Tofacitinib a potential treatment for sarcoidosis: Study
Australia: Tofacitinib, a JAK inhibitor, could be used for the treatment of sarcoidosis, suggests a recent study in the Journal of the American Academy of Dermatology. In a series of cases, the researchers reported successful treatment of five patients having cutaneous sarcoidosis with tofacitinib.
Sarcoidosis is a multi-organ inflammatory disease characterized by noncaseating granulomas. In approx 25% of the cases, cutaneous involvement occurs. Not all the patients require treatment but for those of who do, steroid-sparing agents and corticosteroids may be useful. These agents are not universally effective and their use may be limited by toxicity. So, there arises a need for safe and effective therapies.
Activator of transcription (STAT) pathway and Janus kinase (JAK)-signal transducer seems to play a role in pathogenesis. Some studies have suggested tofacitinib to be involved in the down regulation of JAK-STAT-dependent pathways thereby reducing proinflammatory cytokine levels as implicated in granuloma formation; successful treatment of sarcoidosis with JAK-inhibitors tofacitinib and ruxolitinib have since been reported.
Karolina L. Kerkemeyer, Sinclair Dermatology, East Melbourne, Victoria, Australia, and colleagues report a case series of 5 women with refractory cutaneous sarcoidosis, all of whom responded to oral tofacitinib. Among them, 3 women also had pulmonary sarcoidosis and experienced decreased cough and/or increased exercise tolerance while taking tofacitinib. Tofacitinib was well-tolerated by all patients. The only side effect noted was transient lymphopenia in 1 patient, which spontaneously resolved.
"The study adds to the growing body of literature suggesting a potential role for the use of JAK inhibitors to treat sarcoidosis," wrote the authors.
"Although further prospective studies are necessary, tofacitinib, a JAK inhibitor, may be a potential treatment for sarcoidosis refractory to systemic steroids and other steroid-sparing agents," they concluded.
"Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series," is published in the Journal of the American Academy of Dermatology.
DOI: https://www.jaad.org/article/S0190-9622(20)32827-9/pdf
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.